North America Infectious Disease Diagnostics Market Forecast to 2030

North America Infectious Disease Diagnostics Market Forecast to 2030

North America Infectious Disease Diagnostics Market Forecast to 2030 – Regional Analysis – By Product (Kits & Reagents, Instruments, and Software & Services), Technology (Biosensor-Based, Immunodiagnostics, Molecular-Based Diagnostic Techniques, Clinical Biology, and Others), Application Type (Laboratory Testing and Point-of-Care Testing), Testing Type (Human Testing and Veterinary Testing), and End User (Diagnostic Laboratories, Hospitals & Clinics, Research Institutes, Homecare Settings, and Others)

Send Enquiry
Item ID: BMIRE00025326 Category: Tag:

$2,840 – $4,440

Description

The North America infectious disease diagnostics market was valued at US$ 18,684.43 million in 2022 and is expected to reach US$ 28,718.07 million by 2030; it is estimated to grow at a CAGR of 5.5% from 2022 to 2030.

Increasing Focus on R&D and Funding in Infectious Disease Diagnostics Drive North America Infectious Disease Diagnostics Market

Research and development (R&D) is an essential component of the business of pharmaceutical and biopharmaceutical companies. R&D enables market players to come up with new products for various therapeutic applications with significant medical and commercial potential. Moreover, leading market players invest in R&D to develop advanced technologies and generate more revenue. In response to the growing cases of infectious diseases and the shortage of laboratory capabilities and molecular testing reagents, some diagnostic testing manufacturers offer fast and easy-to-use devices to facilitate out-of-laboratory testing. The simple test kits detect proteins of pathogens from samples or human antibodies that are produced in response to infection in blood or serum.

Following is a list of a few key funding initiatives undertaken by the manufacturers:

– In March 2022, the Global Fund to Fight AIDS, Malaria, and Tuberculosis acclaimed the decision by Canada to contribute CAD 60 million (US$ 43.99 million) to the Global Fund`s COVID-19 Response Mechanism (C19RM). The funding will help provide life-saving diagnostic tests, treatments, and personal protective equipment (PPE) to low- and middle-income countries.

– In September 2021, the Biden-Harris Administration invested US$ 2.1 billion to enhance infection control and prevention activities across the US public health and healthcare sectors. The Biden-Harris administration, operating through the CDC, invested funds in the US rescue programs to address state, local, and territorial health departments and other partner organizations about infectious diseases in the US.

Thus, rising focus on R&D and funding in infectious disease diagnostics is expected to create lucrative opportunities for the growth of the North America infectious disease diagnostics market.

North America Infectious Disease Diagnostics Market Overview

The infectious diseases diagnostics market growth in the US is primarily driven by the increasing prevalence of infectious diseases, rising geriatric population, and growing number of product launches by key players. Aging is a prominent risk factor for infectious diseases as people above 60 generally have compromised immunity. According to a study published by the Population Reference Bureau in 2020, the population of individuals aged 65 and above was 55 million in the US in 2020, and the number is expected to reach 95 million by 2060. Regulatory agencies in the US are imposing favorable policies for the development of point-of-care (POC) products for the diagnosis and treatment of various indications. For instance, in March 2021, the US Food Drug Administration (FDA) authorized Binx Health IO CT/NG Assay for community-based clinics, urgent care settings, and outpatient healthcare facilities; it is the first POC testing product for diagnosing chlamydial and gonorrheal infections. In May 2022, Becton Dickinson and Company (BD), one of the leading global medical technology companies, announced the launch of its new, fully automated, high-throughput molecular diagnostics platform for infectious diseases for the market in the US. The new BD COR MX instrument was launched as an analytical instrument option for the BD COR platform, with 510(k) clearance from the FDA. The BD CTGCTV2 molecular assay, the first test available on the new system, is a single test that detects the three most prevalent non-viral sexually transmitted infections (STIs)-Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV).

North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Million)

North America Infectious Disease Diagnostics Market Segmentation

The North America infectious disease diagnostics market is segmented based on product, technology, application type, testing type, end user, and country.

Based on product, the North America infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held the largest share in 2022.

By technology, the North America infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The immunodiagnostics segment held the largest share in 2022. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.

By application type, the North America infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held a larger share in 2022.

By testing type, the North America infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held a larger share in 2022. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.

By end user, the North America infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held the largest share in 2022.

Based on country, the North America infectious disease diagnostics market is segmented into the US, Canada, and Mexico. The US dominated the North America infectious disease diagnostics market in 2022.

Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA are some of the leading companies operating in the North America infectious disease diagnostics market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

At 5.5% CAGR, the North America Infectious Disease Diagnostics Market is Speculated to be Worth US$ 28,718.07 Million by 2030, Says the Research Team

According to the Research Team’ research, the North America infectious disease diagnostics market was valued at US$ 18,684.43 million in 2022 and is expected to reach US$ 28,718.07 million by 2030, registering a CAGR of 5.5% from 2022 to 2030. Rising number of product approvals and launches and increasing focus on R&D and funding in infectious disease diagnostics are among the critical factors attributed to the North America infectious disease diagnostics market expansion.

The small and big companies operating in the North America infectious disease diagnostics market adopt various strategies such as regional expansion, new product launches, and technological advancements to increase their revenue. Infectious disease diagnostic products are safer and more effective than before with continued developments and technological advancements.

Following are a few recent developments in the North America infectious disease diagnostics market:

In August 2023, Danaher Corp entered into a definitive agreement to acquire Abcam plc. Danaher would acquire all of the outstanding shares of Abcam for US$ 24.00 per share in cash, or a total enterprise valued of approximately US$ 5.7 billion including assumed indebtedness and net of acquired cash.

In January 2022, Cepheid announced that Health Canada had approved the medical device license of Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular diagnostic test for the qualitative detection of viruses causing Flu A, Flu B, COVID-19, and respiratory syncytial virus (RSV) infections from a single patient sample.

In May 2021, Torus Biosystems launched the US$ 25 million program to advance infectious disease diagnostics across healthcare facilities.

In December 2021, Roche launched the first infectious illness tests on the Cobas 5800 System, a new molecular laboratory instrument. Cobas HIV-1/HIV-2 Qualitative, Cobas HBV, cobas HCV, cobas HIV-1, and Cobas Omni Utility Channel kit are a few of these options.

In June 2021, Bio-Rad Laboratories launched PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit, an accurate, sensitive, and cost-effective tool used to detect SARS-CoV-2 in a community’s wastewater.

In April 2020, CerTest Biotec and B.D. (Becton, Dickinson, and Company) announced that VIASURE SARS-CoV-2 Real-Time PCR Detection Kit adapted for the BD MAX System has been CE marked to the IVD Directive (98/79/C.E.).

In November 2020, bioMérieux launched CLARION, its pioneering clinical informatics software that connects diagnostic data in the US.

The active participation of market participants in product innovation and development and an increase in product approvals are likely to boost the growth of the North America infectious disease diagnostics market during the forecast period.

On the contrary, inadequate reimbursement scenario hampers the growth of North America infectious disease diagnostics market.

Based on product, the North America infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held 63.7% share of the North America infectious disease diagnostics market in 2022, amassing US$ 11,897.73 million. It is projected to garner US$ 17,742.90 million by 2030 to expand at 5.1% CAGR during 2022-2030.

By technology, the North America infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The immunodiagnostics segment held 44.3% share of the North America infectious disease diagnostics market in 2022, amassing US$ 8,276.31 million. It is projected to garner US$ 12,467.71 million by 2030 to expand at 5.3% CAGR during 2022-2030. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.

By application type, the North America infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held 69.5% share of the North America infectious disease diagnostics market in 2022, amassing US 12,989.15 million. It is projected to garner US$ 19,504.36 million by 2030 to expand at 5.2% CAGR during 2022-2030.

By testing type, the North America infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held 82.6% share of the North America infectious disease diagnostics market in 2022, amassing US$ 15,431.62 million. It is projected to garner US$ 23,327.46 million by 2030 to expand at 5.3% CAGR during 2022-2030. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.

By end user, the North America infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held 39.9% share of the North America infectious disease diagnostics market in 2022, amassing US 7,459.65 million. It is projected to garner US$ 11,603.54 million by 2030 to expand at 5.7% CAGR during 2022-2030.

Based on country, the North America infectious disease diagnostics market is segmented into US, Canada, and Mexico. The US held 84.2% share of North America infectious disease diagnostics market in 2022, amassing US$ 15,724.81 million. It is projected to garner US$ 23,962.36 million by 2030 to expand at 5.4% CAGR during 2022-2030.

Key players operating in the North America infectious disease diagnostics market are Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA, among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America infectious disease diagnostics market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in North America infectious disease diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the infectious disease diagnostics market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 North America Infectious Disease Diagnostics Market, by Country (US$ Million)
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Infectious Disease Diagnostics Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Rising Incidence of Infectious Diseases
4.1.2 Rising Application of Diagnostics in Veterinary Infectious Disease
4.2 Market Restraints
4.2.1 Inadequate Reimbursement Scenario
4.3 Market Opportunities
4.3.1 Increasing Focus on R&D and Funding in Infectious Disease Diagnostics
4.4 Future Trends
4.4.1 Rising Number of Product Approvals and Launches
4.5 Impact Analysis:
5. Infectious Disease Diagnostics Market – North America Market Analysis
5.1 North America Infectious Disease Diagnostics Market Revenue (US$ Mn), 2022 – 2030
6. North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 – by Product
6.1 Overview
6.2 North America Infectious Disease Diagnostics Market Revenue Share, by Product, 2022 & 2030 (%)
6.3 Kits & Reagents
6.3.1 Overview
6.3.2 Kits & Reagents: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Instruments
6.4.1 Overview
6.4.2 Instruments: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Software & Services
6.5.1 Overview
6.5.2 Software & Services: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 – by Technology
7.1 Overview
7.2 North America Infectious Disease Diagnostics Market Revenue Share, by Technology, 2022 & 2030 (%)
7.3 Biosensor-based
7.3.1 Overview
7.3.2 Biosensor-based: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Immunodiagnostics
7.4.1 Overview
7.4.2 Immunodiagnostics: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology, 2020-2030 (US$ Million)
7.5 Molecular-Based Diagnostic Techniques
7.5.1 Overview
7.5.2 Molecular-Based Diagnostic Techniques: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.5.2.1 North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology, 2020-2030 (US$ Million)
7.6 Clinical Biology
7.6.1 Overview
7.6.2 Clinical Biology: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 – by Application Type
8.1 Overview
8.2 North America Infectious Disease Diagnostics Market Revenue Share, by Application Type, 2022 & 2030 (%)
8.3 Point-of-Care Testing
8.3.1 Overview
8.3.2 Point-of-Care Testing: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Laboratory Testing
8.4.1 Overview
8.4.2 Laboratory Testing: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 – by Testing Type
9.1 Overview
9.2 North America Infectious Disease Diagnostics Market Revenue Share, by Testing Type, 2022 & 2030 (%)
9.3 Human Testing
9.3.1 Overview
9.3.2 Human Testing: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
9.3.2.1 North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type, 2020-2030 (US$ Million)
9.4 Veterinary Testing
9.4.1 Overview
9.4.2 Veterinary Testing: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 – by End User
10.1 Overview
10.2 North America Infectious Disease Diagnostics Market Revenue Share, by End User, 2022 & 2030 (%)
10.3 Diagnostic Laboratories
10.3.1 Overview
10.3.2 Diagnostic Laboratories: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Hospitals and Clinics
10.4.1 Overview
10.4.2 Hospitals and Clinics: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Research Institutes
10.5.1 Overview
10.5.2 Research Institutes: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.6 Homecare Settings
10.6.1 Overview
10.6.2 Homecare Settings: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.7 Others
10.7.1 Overview
10.7.2 Others: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
11. North America Infectious Disease Diagnostics Market – Country Analysis
11.1 North America Infectious Disease Diagnostics Market – Country Analysis
11.1.1 North America Infectious Disease Diagnostics Market, by Country
11.1.1.1 US
11.1.1.1.1 Overview
11.1.1.1.2 US: North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.1.3 US: North America Infectious Disease Diagnostics Market, by Product, 2020-2030 (US$ Million)
11.1.1.1.4 US: North America Infectious Disease Diagnostics Market, by Technology, 2020-2030 (US$ Million)
11.1.1.1.4.1 US: North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology, 2020-2030 (US$ Million)
11.1.1.1.4.2 US: North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology, 2020-2030 (US$ Million)
11.1.1.1.5 US: North America Infectious Disease Diagnostics Market, by Application Type, 2020-2030 (US$ Million)
11.1.1.1.6 US: North America Infectious Disease Diagnostics Market, by Testing Type, 2020-2030 (US$ Million)
11.1.1.1.6.1 US: North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type, 2020-2030 (US$ Million)
11.1.1.1.7 US: North America Infectious Disease Diagnostics Market, by End User, 2020-2030 (US$ Million)
11.1.1.2 Canada
11.1.1.2.1 Overview
11.1.1.2.2 Canada: North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.2.3 Canada: North America Infectious Disease Diagnostics Market, by Product, 2020-2030 (US$ Million)
11.1.1.2.4 Canada: North America Infectious Disease Diagnostics Market, by Technology, 2020-2030 (US$ Million)
11.1.1.2.4.1 Canada: North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology, 2020-2030 (US$ Million)
11.1.1.2.4.2 Canada: North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology, 2020-2030 (US$ Million)
11.1.1.2.5 Canada: North America Infectious Disease Diagnostics Market, by Application Type, 2020-2030 (US$ Million)
11.1.1.2.6 Canada: North America Infectious Disease Diagnostics Market, by Testing Type, 2020-2030 (US$ Million)
11.1.1.2.6.1 Canada: North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type, 2020-2030 (US$ Million)
11.1.1.2.7 Canada: North America Infectious Disease Diagnostics Market, by End User, 2020-2030 (US$ Million)
11.1.1.3 Mexico
11.1.1.3.1 Overview
11.1.1.3.2 Mexico: North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.3.3 Mexico: North America Infectious Disease Diagnostics Market, by Product, 2020-2030 (US$ Million)
11.1.1.3.4 Mexico: North America Infectious Disease Diagnostics Market, by Technology, 2020-2030 (US$ Million)
11.1.1.3.4.1 Mexico: North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology, 2020-2030 (US$ Million)
11.1.1.3.4.2 Mexico: North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology, 2020-2030 (US$ Million)
11.1.1.3.5 Mexico: North America Infectious Disease Diagnostics Market, by Application Type, 2020-2030 (US$ Million)
11.1.1.3.6 Mexico: North America Infectious Disease Diagnostics Market, by Testing Type, 2020-2030 (US$ Million)
11.1.1.3.6.1 Mexico: North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type, 2020-2030 (US$ Million)
11.1.1.3.7 Mexico: North America Infectious Disease Diagnostics Market, by End User, 2020-2030 (US$ Million)
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Abbott Laboratories
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Bruker Corp
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Cardinal Health Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 F. Hoffmann-La Roche Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Trinity Biotech Plc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Danaher Corp
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Bio-Rad Laboratories Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 ACON Laboratories Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 DiaSorin SpA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Infectious Disease Diagnostics Market Segmentation
Table 2. Infectious Diseases and Fundings
Table 3. North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type – Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America Infectious Disease Diagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 7. US: North America Infectious Disease Diagnostics Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 8. US North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 9. US: North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 10. US: North America Infectious Disease Diagnostics Market, by Application Type – Revenue and Forecast to 2030 (US$ Million)
Table 11. US: North America Infectious Disease Diagnostics Market, by Testing Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. US: North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. US: North America Infectious Disease Diagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 14. Canada: North America Infectious Disease Diagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 15. Canada: North America Infectious Disease Diagnostics Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 16. Canada: North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 17. Canada: North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 18. Canada: North America Infectious Disease Diagnostics Market, by Application Type – Revenue and Forecast to 2030 (US$ Million)
Table 19. Canada: North America Infectious Disease Diagnostics Market, by Testing Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. Canada: North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type – Revenue and Forecast to 2030 (US$ Million)
Table 21. Canada: North America Infectious Disease Diagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 22. Mexico: North America Infectious Disease Diagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 23. Mexico: North America Infectious Disease Diagnostics Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 24. Mexico: North America Infectious Disease Diagnostics Market, for Immunodiagnostics by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 25. Mexico: North America Infectious Disease Diagnostics Market, for Molecular-Based Diagnostic Techniques by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 26. Mexico: North America Infectious Disease Diagnostics Market, by Application Type – Revenue and Forecast to 2030 (US$ Million)
Table 27. Mexico: North America Infectious Disease Diagnostics Market, by Testing Type – Revenue and Forecast to 2030 (US$ Million)
Table 28. Mexico: North America Infectious Disease Diagnostics Market, for Human Testing by Testing Type – Revenue and Forecast to 2030 (US$ Million)
Table 29. Mexico: North America Infectious Disease Diagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 30. Organic Developments Done By Companies
Table 31. Inorganic Developments Done By Companies
Table 32. Glossary of Terms, North America Infectious Disease Diagnostics Market
 

LIST OF FIGURES

Figure 1. North America Infectious Disease Diagnostics Market Segmentation, By Country
Figure 2. North America Infectious Disease Diagnostics Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Infectious Disease Diagnostics Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America Infectious Disease Diagnostics Market Revenue Share, by Product, 2022 & 2030 (%)
Figure 6. Kits & Reagents: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Instruments: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Software & Services: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Infectious Disease Diagnostics Market Revenue Share, by Technology, 2022 & 2030 (%)
Figure 10. Biosensor-based: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Immunodiagnostics: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Molecular-Based Diagnostic Techniques: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Clinical Biology: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. North America Infectious Disease Diagnostics Market Revenue Share, by Application Type, 2022 & 2030 (%)
Figure 16. Point-of-Care Testing: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Laboratory Testing: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Infectious Disease Diagnostics Market Revenue Share, by Testing Type, 2022 & 2030 (%)
Figure 19. Human Testing: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Veterinary Testing: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Infectious Disease Diagnostics Market Revenue Share, by End User, 2022 & 2030 (%)
Figure 22. Diagnostic Laboratories: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Hospitals and Clinics: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Research Institutes: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Homecare Settings: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Others: North America Infectious Disease Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. North America: Infectious Disease Diagnostics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 28. North America Infectious Disease Diagnostics Market, By Key Countries, 2022 and 2030 (%)
Figure 29. US: North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Canada: North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Mexico: North America Infectious Disease Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Growth Strategies Done by the Companies in the Market, (%)

The List of Companies – North America Infectious Disease Diagnostics Market

1. Abbott Laboratories
2. ACON Laboratories Inc
3. Bio-Rad Laboratories Inc
4. Bruker Corp
5. Cardinal Health Inc
6. Danaher Corp
7. DiaSorin SpA
8. F. Hoffmann-La Roche Ltd
9. Trinity Biotech Plc

Reviews

There are no reviews yet.

Be the first to review “North America Infectious Disease Diagnostics Market Forecast to 2030”